Skip to main content

Table 2 Univariate analysis for overall survival

From: Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

  Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age (years) < 58 years 1    0.913     
≥58 years 1.03 0.57 1.86      
Sex Male 1    0.831     
Female 0.94 0.51 1.73      
Disease presentation Recurrent 1    0.327     
Metastatic 1.42 0.70 2.89      
Differentiation WD 1    0.602     
MD 4.94 0.61 39.76      
PD 4.41 0.59 32.82      
SRC 3.41 0.44 26.72      
Others* 3.64 0.38 35.20      
HER2 Negative 1    0.892     
Positive 0.81 0.34 1.93      
Palliative chemotherapy history No 1    0.003 1    0.005
Yes 4.19 1.63 10.78   10.78 2.05 56.81  
Molecular subtype of primary tumor MSI 0.87 0.11 6.64 0.143     
EBV 19.11 1.90 192.25      
CIN-like 1.01 0.49 2.07      
GS-like 1        
Unknown 1.33 0.63 2.84      
VEGF-A (pg/mL) < 100.9 pg/mL 1    0.127     
≥100.9 pg/mL 1.58 0.88 2.86      
IL-10 (pg/mL) > 243.8 pg/mL 1    0.16     
≥243.8 pg/mL 1.64 0.82 3.25      
TGF-β1 (pg/mL) < 393.6 pg/mL 1    0.197     
≥393.6 pg/mL 1.97 0.70 5.55      
Cytokine-scoring model 0–1 1    0.037     
(number of high level of cytokines) 2–3 1.91 1.04 3.49      
CD4/CD3 (%) < 41.7% 1    0.232     
≥41.7% 0.65 0.32 1.32      
CD8/CD3 (%) < 33.3% 1    0.272     
≥33.3% 1.58 0.70 3.57      
CD4/CD8 ratio < 0.6 1    0.034     
≥0.6 0.35 0.13 0.92      
CD8CD45RO+/CD8 (%) < 67.2% 1    0.021 1    0.019
≥67.2% 2.54 1.15 5.59   3.25 1.22 8.68  
CD8CD25+/CD8 (%) < 1.6% 1    0.081     
≥1.6% 1.92 0.92 3.99      
CD8CD69+/CD8 (%) < 28.0% 1    0.054     
≥28.0% 2.09 0.99 4.41      
CD8HLA-DR+/CD8 (%) < 28.4% 1    0.008 1    0.012
≥28.4% 3.77 1.43 9.96   5.36 1.45 19.88  
CD8 TIM3+/CD8 (%) < 0.2% 1    0.082     
≥0.2% 0.50 0.23 1.09      
CD8 LAG3+/CD8 (%) < 3.7% 1    0.098     
≥3.7% 1.92 0.89 4.17      
CD8 PD1+/CD8 (%) < 50.2% 1    0.038     
≥50.2% 2.58 1.06 6.31      
CD3 PD1+/CD3 (%) < 17.2% 1    0.001 1    < 0.001
≥17.2% 3.53 1.66 7.52   8.61 2.81 26.37  
CD4 PD1+/CD4 (%) < 32.1% 1    0.052     
≥32.1% 2.11 0.99 4.50      
FoxP3+ Tregs (No) < 380 1    0.029 1    0.001
≥380 0.40 0.18 0.91   0.13 0.04 0.42  
PD-L1 positive tumor cells (%) < 1% 1    0.87     
≥1% 1.07 0.49 2.34      
  1. VEGF vascular endothelial growth factor, IL interleukin, TGF-β1 transforming growth factor- beta1, CD cluster of differentiation, WD well differentiated, MD moderate differentiated, PD poorly differentiated, SRC signet ring cell carcinoma, MSI microsatellite instability, EBV Epstein-Barr virus, CIN chromosomal instability, GS genomically stable, HR hazard ratio, CI confidence interval, P p-value, No number
  2. Others*: mucinous adenocarcinoma, undifferentiated carcinoma